comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 20:06:21 - browse：78948

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Lack of health data on LGBTQ+ people has serious consequences

explore

WSS

Medicare drug price negotiation hearing pits pharma v Biden admin

Weight loss drugs aren’t covered by Obamacare. That may change

Congress may force more Covid

Medicare Advantage enrollment grows 7.1% to 33.4 million people

A new drug could help frostbite victims avoid its ravages

Measles policy set amid Florida outbreak alarms vaccine proponents

hotspot

comprehensive

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Why Talkspace is targeting Medicare, a tricky market

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The untold story of TV’s first prescription drug ad

Medicare details structure of new drug price negotiation program

Harvard's David Sinclair gets blowback over aging

DIEP, the 'gold standard' of breast reconstruction, is under threat

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

ChatGPT in medicine: STAT answers readers' burning questions

State of the Union pitch: Bigger Medicare drug price negotiations

leisure time

Surprise medical billing ban raises prices elsewhere

Ozempic has benefits for kidney disease as well as diabetes

Reporting on presidential health from Reagan to Trump and Biden

Readout Newsletter: BridgeBio, Akero, and human embryo models

Families look for replacement for GSK asthma drug Flovent

Congress may force more Covid

focus

explore

hotspot

explore